Genomics doesn't merely have massive potential, it's the backbone of research in cancer, even if the diagnostics are slimmed down to simple PCR tests or to even antibody staining on a slide, or to assigning drugs.
In some of the big cancers, sequencing is even a primary diagnostic:
* breast cancer: gene expression signatures are standard for determining the necessity of chemo
* colon: blood based sequencing for KRAS mutation is extremely common
* lung: matching kinase inhibitors to EGFR mutations is essential for therapy
* all solid tumors: tumor mutation burden is a companion diagnostic for the major immune checkpoint therapies that have revolutionized treatment over the past decade.
I know of almost no cancer that has not had massive changes in treatment, due to accelerated research possibly only through extensive use of genomics.